Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use

US6743790B2 · kind B2 · utility

Assignee

• Aventis Pharma Deutschland GmbH · DE

Inventors

• Otmar Klingler · Rodgau, DE
• Manfred Schudok · Eppstein, DE
• Hans-Peter Nestler · Kelkheim, DE
• Hans Matter · Langenselbold, DE
• Herman Schreuder · Frankfurt am Main, DE

Key dates

• Filing date: Jun 6, 2001
• Grant date: Jun 1, 2004
• Expiry date: Jun 6, 2021

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C2603/18
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds of the formula I, in which R1, R2, R3, R4, R5, R6, A, X, m and n have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of thromboembolic diseases and restenoses. They are reversible inhibitors of the blood clotting enzyme factor VIIa and can in general be applied in conditions in which an undesired activity of factor VIIa is present or for the cure or prevention of which an inhibition of factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, for example as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.